Tadocizumab

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Tadocizumab
Monoclonal antibody
Type Fab fragment
Source Humanized (from mouse)
Target Integrin αIIbβ3
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
Formula C2107H3252N562O673S12
Molar mass 47.6 kg/mol
 NYesY (what is this?)  (verify)

Tadocizumab is a humanized monoclonal antibody that acts on the cardiovascular system.[1] It binds to integrin αIIbβ3, a fibrinogen and fibronectin receptor found on platelets.[2]

The drug is designed for the treatment of patients undergoing percutaneous coronary interventions. It was developed by Yamanōchi Pharma America, Inc.[1]

References[edit]

  1. ^ a b Statement On A Nonproprietary Name Adopted By The USAN Council - Tadocizumab, American Medical Association.
  2. ^ Molecular cell biology. Lodish, Harvey F. 5. ed. : – New York : W. H. Freeman and Co., 2003, 973 s. b ill. ISBN 0-7167-4366-3